Low serum testosterone increases mortality risk among male dialysis patients

Journal of the American Society of Nephrology

Volumn 20, Issue 3, 2009, Pages 613-620

  Carrero, Juan Jesús ^a,d   Qureshi, Abdul Rashid ^a   Parini, Paolo ^b   Arver, Stefan ^c   Lindholm, Bengt ^a   Bárány, Peter ^a   Heimbürger, Olof ^a   Stenvinkel, Peter ^a,d  

^a Divisions of Baxter Novum and Renal Medicine   (Sweden)

^b Department of Laboratory Medicine ^*  (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIANEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; PENTRAXIN 3; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; AGED; ANDROGEN DEFICIENCY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG USE; FOLLOW UP; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPOGONADISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; TESTOSTERONE BLOOD LEVEL;

EID: 62149122026     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2008060664     Document Type: Article

References (48)

1. Rhoden EL, Morgentaler A: Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 350: 482-492, 2004
2. Laughlin GA, Barrett-Connor E, Bergstrom J: Low serum testosterone and mortality in older men. J Clin Endocrinol Merafo 93: 68-75, 2008
3. Araujo AB, Kupelian V, Page ST, Handelsman DJ, Bremner WJ, McKinlay JB: Sex steroids and all-cause and cause-specific mortality in men. Arch Intern Med 167: 1252-1260, 2007
4. Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR: Low serum testosterone and mortality in male veterans. Arch Intern Med 166: 1660-1665, 2006
5. Khaw KT, Dowsett M, Folkerd E, Bingham S, Wareham N, Luben R, Welch A, Day N: Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 116: 2694-2701, 2007
6. Foley RN, Parfrey PS, Sarnak MJ: Clinical epidemiology of cardiovascular disease in chronic renal failure. Am J Kidney Dis 32[Suppl 5]: S112-S119, 1998
7. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305, 2004
8. Stenvinkel P, Carrero J J, Axelsson J, Lindholm B, Heimburger O, Massy Z: Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: How do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 3: 505-521, 2008
9. Elsayed EF, Tighiouart H, Griffith J, Kurth T, Levey AS, Salem D, Sarnak MJ, Weiner DE: Cardiovascular disease and subsequent kidney disease. Arch Intern Med 167: 1130-1136, 2007
10. Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N: Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 20: 1048-1056, 2005
11. Handelsman DJ: Hypothalamic-pituitary gonadal dysfunction in renal failure, dialysis and renal transplantation. Endocr Rev 6: 151-182, 1985
12. Albaaj F, Sivalingham M, Haynes P, McKinnon G, Foley RN, Waldek S, O'Donoghue DJ, Kalra PA: Prevalence of hypogonadism in male patients with renal failure. Postgrad Med J 82: 693-696, 2006
13. Gomez F, de la Cueva R, Wauters JP, Lemarchand-Beraud T: Endocrine abnormalities in patients undergoing long-term hemodialysis. The role of prolactin. Am J Med 68: 522-530, 1980
14. Handelsman DJ, Dong Q: Hypothalamo-pituitary gonadal axis in chronic renal failure. Endocrinol Metab Clin North Am 22: 145-161, 1993
15. de Vries CP, Gooren LJ, Oe PL: Haemodialysis and testicular function. Int JAndrol 7: 97-103, 1984
16. Johansen KL: Testosterone metabolism and replacement therapy in patients with end-stage renal disease. Semin Dial 17: 202-208, 2004
17. Doumouchtsis KK, Kostakis Al, Doumouchtsis SK, Grapsa El, Passali- dou IA, Tziamalis MP, Poulakou MV, Vlachos IS, Perrea DN: The effect of sexual hormone abnormalities on proximal femur bone mineral density in hemodialysis patients and the possible role of RANKL. Hemodial Int 12: 100-107, 2008
18. Karakitsos D, Patrianakos AP, De Groot E, Boletis J, Karabinis A, Kyriazis J, Samonis G, Parthenakis Fl, Vardas PE, Daphnis E: Androgen deficiency and endothelial dysfunction in men with end-stage kidney disease receiving maintenance hemodialysis. Am J Nephrol 26: 536- 543, 2006
19. Basaria S, Dobs AS: Testosterone making an entry into the cardiom-etabolic world. Circulation 116: 2658-2661, 2007
20. Stewart-Bentley M, Gans D, Horton R: Regulation of gonadal function in uremia. Metabolism 23: 1065-1072, 1974
21. Singh AB, Norris K, Modi N, Sinha-Hikim I, Shen R, Davidson T, Bhasin S: Pharmacokinetics of a transdermal testosterone system in men with end stage renal disease receiving maintenance hemodialysis and healthy hypogonadal men. J Clin Endocrinol Metab 86: 2437-2445, 2001
22. Muller M, van der Schouw YT, Thijssen JH, Grobbee DE: Endogenous sex hormones and cardiovascular disease in men. J Clin Endocrinol Metab 88: 5076-5086, 2003
23. Kupelian V, Page ST, Araujo AB, Travison TG, Bremner WJ, McKinlay JB: Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 91: 843-850, 2006
24. Miller KK: Androgen deficiency: Effects on body composition. Pituitary, 2008, Epub ahead of print
25. Heimburger O, Qureshi AR, Blaner WS, Berglund L, Stenvinkel P: Hand-grip muscle strength, lean body mass, and plasma proteins as markers of nutritional status in patients with chronic renal failure close to start of dialysis therapy. Am J Kidney Dis 36: 1213-1225, 2000
26. Brodsky IG, Balagopal P, Nair KS: Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men: A clinical research center study. J Clin Endocrinol Metab 81: 3469-3475, 1996
27. Johansen KL, Painter PL, Sakkas GK, Gordon P, Doyle J, Shubert T: Effects of resistance exercise training and nandrolone decanoate on body composition and muscle function among patients who receive hemodialysis: A randomized, controlled trial. J Am Soc Nephrol 17: 2307-2314, 2006
28. Ferrucci L, Maggio M, Bandinelli S, Basaria S, Lauretani F, Ble A, Valenti G, Ershler WB, Guralnik JM, Longo DL: Low testosterone levels and the risk of anemia in older men and women. Arch Intern Med 166: 1380-1388, 2006 1: 8-13, 1987
29. Navarro JF, Mora C, Macia M, Garcia J: Randomized prospective comparison between erythropoietin and androgens in CARD patients. Kidney Int 61: 1537-1544, 2002
30. Kapoor D, Clarke S, Stanworth R, Channer KS, Jones TH: The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur J Endocrinol 156: 595-602, 2007
31. Metcalfe PD, Leslie JA, Campbell MT, Meldrum DR, Hile KL, Meldrum KK: Testosterone exacerbates obstructive renal injury by stimulating TNF-alpha production and increasing proapoptotic and profibrotic signaling. Am J Physiol Endocrinol Metab 294: E435-E443, 2008
32. Li S, Li X, Li Y: Regulation of atherosclerotic plaque growth and stability by testosterone and its receptor via influence of inflammatory reaction. Vascul Pharmacol, 49: 14-18, 2008
33. Barrett-Connor E, Khaw KT: Endogenous sex hormones and cardiovascular disease in men. A prospective population-based study. Circulation 78: 539-545, 1988
34. Hak AE, Witteman JC, de Jong FH, Geerlings Ml, Hofman A, Pols HA: Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: The Rotterdam study. J Clin Endocrinol Metab 87: 3632-3639, 2002
35. Muller M, van den Beld AW, Bots ML, Grobbee DE, Lamberts SW, van der Schouw YT: Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation 109: 2074-2079, 2004
36. Jones RD, Pugh PJ, Jones TH, Channer KS: The vasodilatory action of testosterone: A potassium-channel opening or a calcium antagonistic action? Br J Pharmacol 138: 733-744, 2003
37. Webb CM, McNeill JG, Hayward CS, de Zeigler D, Collins P: Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation 100: 1690-1696, 1999
38. Allan CA, Strauss BJ, Burger HG, Forbes EA, McLachlan Rl: Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. J Clin Endocrinol Metab 93: 139-146, 2008
39. Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, Aleman A, Lock TM, Bosch JL, Grobbee DE, van der Schouw YT: Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: A randomized controlled trial. JAMA 299: 39-52, 2008
40. Grinspoon S, Corcoran C, Lee K, Burrows B, Hubbard J, Katznelson L, Walsh M, Guccione A, Cannan J, Heller H, Basgoz N, Klibanski A: Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting. J Clin Endocrinol Metab 81: 4051-4058, 1996
41. Karila TA, Sarkkinen P, Marttinen M, Seppala T, Mero A, Tallroth K: Rapid weight loss decreases serum testosterone. Int J Sports Med, 29: 872-877, 2008
42. Vermeulen A, Verdonck G: Representativeness of a single point plasma testosterone level for the long term hormonal milieu in men. J Clin Endocrinol Metab 74: 939-942, 1992
43. Carrero JJ, Qureshi AR, Axelsson J, Avesani CM, Suliman ME, Kato S, Barany P, Snaedal-Jonsdottir S, Alvestrand A, Heimburger O, Lind- holm B, Stenvinkel P: Comparison of nutritional and inflammatory markers in dialysis patients with reduced appetite. Am J Clin Nutr 85: 695-701, 2007
44. Vermeulen A, Verdonck L, Kaufman JM: A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84: 3666-3672, 1999
45. Morris PD, Malkin CJ, Channer KS, Jones TH: A mathematical comparison of techniques to predict biologically available testosterone in a cohort of 1072 men. Eur J Endocrinol 151: 241-249, 2004
46. Lunenfeld B, Saad F, Hoesl CE: ISA, ISSAM and EAU recommendations for the investigation, treatment and monitoring of late-onset hypogonadism in males: Scientific background and rationale. Aging Male 8: 59-74, 2005
47. Vermeulen A, Kaufman JM: Diagnosis of hypogonadism in the aging male. Aging Male 5: 170-176, 2002
48. Detsky AS, McLaughlin JR, Baker JP, Johnston N, Whittaker S, Men- delson RA, Jeejeebhoy KN: What is subjective global assessment of nutritional status? J Parenter Enteral Nutr 11: 8-13, 1987